ROIV
Roivant Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$37.52
+1.10%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 155.72x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 6.41x
- Price / sales
- 3598.19x
- Price / cash flow
- -33.49x
Enterprise value
- Enterprise value
- $24.1B
- EV / sales
- 3194.00x
- EV / EBITDA
- -83.81x
- EV / EBIT
- -17.61x
- Market cap
- $27.1B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026